Biotech Values

[rsox]

what are the chances the vrtx hcv candidate may run into "issues" given how far down the road they are in their trial.

what are the chances the idenix hcv candidate may run into "issues" given how far down the road they are in their trial.

which drug may not be able to fully prove itself to even make it to market once all trials are completed.

might one of these drugs prove itself incapable of being tolerated.

the nm issue on the radar seems to be whether the dosing will be higher or lower dosages.
the vx-950 issue on the radar screen is not as clear to me because i am not entirely sure how far they have studied their drug in comparable trials to nm.

nobody really knows whether either of these drugs will ever make it to mkt simply because noone is prescient.